Intended for healthcare professionals

  1. News & Views
  2. Should people at low...
  3. Should people at low risk of cardiovascular disease take a statin?
Analysis

Should people at low risk of cardiovascular disease take a statin?

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6123 (Published 22 October 2013) Cite this as: BMJ 2013;347:f6123

Data supplement

Related articles

See more

Cited by...

  • Statins for primary prevention: what is the regulators role?
  • Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
  • Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
  • Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners perspectives on a facilitated relay intervention in Alberta, Canada
  • Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care
  • Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort
  • Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
  • Should all medical research be published? The moral responsibility of medical journal editors
  • Sackler Colloquium on Improving the Reproducibility of Scientific Research: Misrepresentation and distortion of research in biomedical literature
  • Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease
  • Statin initiations and QRISK2 scoring in UK general practice: a THIN database study
  • Statin-prescribing trends for primary and secondary prevention of cardiovascular disease
  • Patient preferences for cardiovascular preventive medication: a systematic review
  • A content analysis of the representation of statins in the British newsprint media
  • Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
  • Challenges and opportunities in accessing trial data: an example from statin primary prevention trials
  • Cholesterol paradox: a correlate does not a surrogate make
  • High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease
  • Providing additional information about the benefits of statins in a leaflet for patients with coronary heart disease: a qualitative study of the impact on attitudes and beliefs
  • Cohort study investigating the relationship between cholesterol, cardiovascular risk score and the prescribing of statins in UK primary care: study protocol
  • Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data
  • Media coverage of statins may have led to 2000 cardiovascular events
  • Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
  • Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study
  • Patients who discontinued statin treatment: a protocol for cohort study using primary care data
  • Coronary artery disease in the military patient
  • Dyslipidaemia and the military patient
  • Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis
  • The statin diabetes conundrum: short-term gain, long-term risk or inconvenient truth?
  • Statins for people at low risk
  • Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA)
  • Electronic health records may threaten blinding in trials of statins
  • Report of the independent panel considering the retraction of two articles in The BMJ
  • Risks in the balance: the statins row
  • Statins and The BMJ
  • Two papers in The BMJ with statin side effect errors shouldn't be retracted, independent panel concludes
  • Six professors back NICE guidance on extending use of statins
  • A chasm of misunderstanding: The widening gap between public perception and scientific consensus
  • Retraction of statins article is not in the public interest: better characterisation of benefits and risks is crucial
  • The BMJ statins papers misrepresent the facts
  • (Mis)interpreting studies on the adverse effects of statins
  • Muscular adverse effects are common with statins
  • Adverse effects of statins
  • New analysis fuels debate on merits of prescribing statins to low risk people
  • Authors' reply to Huffman and colleagues
  • Davis and Dietrich's response to Abramson and colleagues' article on statins in low risk people
  • Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people
  • Authors' reply to Davis and Dietrich
  • Statins for the primary prevention of cardiovascular disease
  • Editor's reply to Smith
  • Increasing the use of statins in people at low cardiovascular risk is difficult
Back to top